Bhavana “Tina” Bhatnagar, DO, discusses the mechanism of action of uproleselan, the potential efficacy and safety benefits of adding this agent to standard therapeutic regimens in patients with AML, and the importance of considering MRD negativity as an end point in AML clinical trials.
Cogent Biosciences Announces Positive Updated Clinical Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Cogent Biosciences to Host Investor Webcast on June 10, 2022 at 8:00am ET streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.